echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > "Jianzhi" $8 billion Erye Pharmaceutical Rivaroxaban Tablets Enters Administrative Approval Stage

    "Jianzhi" $8 billion Erye Pharmaceutical Rivaroxaban Tablets Enters Administrative Approval Stage

    • Last Update: 2022-05-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A few days ago, the official website of the State Food and Drug Administration showed that Suzhou Erye Pharmaceutical entered the administrative approval stage by imitating Class 4 rivaroxaban tablets
    .
    According to data from Minet.
    com, global sales of rivaroxaban in 2021 will exceed 8 billion US dollars; terminal sales in Chinese public medical institutions will exceed 3 billion yuan in 2020, with a year-on-year increase of 56.
    57% in the first half of 2021
    .
    Rivaroxaban is an oral anticoagulant that directly inhibits factor Xa jointly developed by Bayer and Johnson & Johnson, with global sales exceeding $8 billion in 2021
    .
    Terminal rivaroxaban tablet sales in China's public medical institutions in recent years (unit: 100 million yuan) Source: MINET And the sales of terminal rivaroxaban tablets in township health centers (referred to as Chinese public medical institutions) exceeded 3 billion yuan; in the first half of 2021, it increased by 56.
    57% year-on-year, and it is the TOP1 product of antithrombotic drugs.
    Among them, Bayer has the largest market share
    .
    2021H1 China's public medical institutions' terminal antithrombotic drug products TOP5 Source: Minet.
    com China's public medical institutions' terminal competition landscape At present, nearly 30 companies have the production approval of rivaroxaban tablets, Yichang Renfu Pharmaceutical, Tiandi Hengyi Pharmaceutical, More than 20 companies, including Lepu Pharmaceuticals and Jiangsu Tasly Diyi Pharmaceuticals, are under review, while Suzhou Erye Pharmaceutical has entered the stage of administrative approval
    .
    Source: State Food and Drug Administration official website, Minet database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.